Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2970]

ESMO 2017: Cancer patients struggle with key aspects of clinical trials

ESMO 2017: Cancer patients struggle with key aspects of clinical trials

ESMO 2017: Study shows ESMO Magnitude of Benefit Scale can be used to grade orphan drugs

ESMO 2017: Study shows ESMO Magnitude of Benefit Scale can be used to grade orphan drugs

European Alliance for Personalised Medicine discusses historic FDA approval for CAR T-cell therapy

European Alliance for Personalised Medicine discusses historic FDA approval for CAR T-cell therapy

ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer

ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer

ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer

ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer

Handheld 'pen' may bring real-time cancer diagnosis to surgeons' fingertips

Handheld 'pen' may bring real-time cancer diagnosis to surgeons' fingertips

ESMO 2017: DNA sequencing could open up new drug indications for patients with rare cancers

ESMO 2017: DNA sequencing could open up new drug indications for patients with rare cancers

ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments

ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments

Cancer immunotherapy gets a boost by disabling specific T cells

Cancer immunotherapy gets a boost by disabling specific T cells

Immunotherapy combination safe and 62 percent effective in metastatic melanoma patients

Immunotherapy combination safe and 62 percent effective in metastatic melanoma patients

More from ecancer